This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lopez, G. N. Articles by Kushner, P. J. Search for Related Content PubMed PubMed Citation Articles by Lopez, G. N. Articles by Kushner, P. J.

Titration by Estrogen Receptor Activation Function-2 of Targets That Are Downstream from Coactivators

Metabolic Research Unit (G.N.L., P.W., J.H.S., J.D.B., P.J.K.) University of California San Francisco, California 94143
Ben May Institute (G.L.G) University of Chicago Chicago, Illinois 60637

Cross-interference (squelching) among nuclear receptors has been proposed to reflect the titration of coactivators that bind the receptors in a hormone-dependent manner. We have tested whether the coactivators are the only target titrated during squelching of one receptor by another, or whether proteins needed for coactivator function are titrated as well. That the coactivators are indeed one target of squelching is apparent. The isolated ligand-binding domain of the estrogen receptor (ER-LBD) squelches transcriptional activation by the thyroid hormone receptor (TR) only when the LBD is bound to ligands that promote coactivator interactions and only when regions of the LBD that promote coactivator interactions are undisturbed. Furthermore, the ER-LBD and the TR compete in vitro for the related p160 coactivators, SRC1a and GRIP1 (glucocorticoid receptor interacting protein 1), or the putative corepressor, RIP140. Finally TR action becomes more potent when coactivator levels are raised. Nonetheless, supplying excess SRC1a or GRIP1 does not abolish squelching by the ER. In fact, squelching becomes even more severe when coactivators are abundant. Supplying combinations of coactivators from the p160 class and the CREB-binding protein (CBP)/p300 class makes squelching most severe. Elevated RIP140 inhibits TR action, but also protects the residual TR action from squelching by the ER-LBD. We conclude that ER-LBD squelches TR both by titrating p160-CBP coactivators and additionally by cooperating with the coactivators to titrate a second factor. The second factor would be needed by the TR for coactivator-mediated transcriptional stimulation.

This article has been cited by other articles:

				R. S. Sane, D. J. Buckley, A. R. Buckley, S. C. Nallani, and P. B. Desai Role of Human Pregnane X Receptor in Tamoxifen- and 4-Hydroxytamoxifen-Mediated CYP3A4 Induction in Primary Human Hepatocytes and LS174T Cells Drug Metab. Dispos., May 1, 2008; 36(5): 946 - 954. [Abstract] [Full Text] [PDF]

				Y. Sainte Marie, A. Toulon, R. Paus, E. Maubec, A. Cherfa, M. Grossin, V. Descamps, M. Clemessy, J.-M. Gasc, M. Peuchmaur, et al. Targeted Skin Overexpression of the Mineralocorticoid Receptor in Mice Causes Epidermal Atrophy, Premature Skin Barrier Formation, Eye Abnormalities, and Alopecia Am. J. Pathol., September 1, 2007; 171(3): 846 - 860. [Abstract] [Full Text] [PDF]

				K. E. Fox, D. M. Fankell, P. F. Erickson, S. M. Majka, J. T. Crossno Jr., and D. J. Klemm Depletion of cAMP-response Element-binding Protein/ATF1 Inhibits Adipogenic Conversion of 3T3-L1 Cells Ectopically Expressing CCAAT/Enhancer-binding Protein (C/EBP) {alpha}, C/EBP beta, or PPAR{gamma}2 J. Biol. Chem., December 29, 2006; 281(52): 40341 - 40353. [Abstract] [Full Text] [PDF]

				S. Glaros, N. Atanaskova, C. Zhao, D. F. Skafar, and K. B. Reddy Activation Function-1 Domain of Estrogen Receptor Regulates the Agonistic and Antagonistic Actions of Tamoxifen Mol. Endocrinol., May 1, 2006; 20(5): 996 - 1008. [Abstract] [Full Text] [PDF]

				A. Pedram, M. Razandi, D. C. Wallace, and E. R. Levin Functional Estrogen Receptors in the Mitochondria of Breast Cancer Cells Mol. Biol. Cell, May 1, 2006; 17(5): 2125 - 2137. [Abstract] [Full Text] [PDF]

				E. T. Alarid, M. T. Preisler-Mashek, and N. M. Solodin Thyroid Hormone Is an Inhibitor of Estrogen-Induced Degradation of Estrogen Receptor-{alpha} Protein: Estrogen-Dependent Proteolysis Is Not Essential for Receptor Transactivation Function in the Pituitary Endocrinology, August 1, 2003; 144(8): 3469 - 3476. [Abstract] [Full Text] [PDF]

				T. Fujita, Y. Kobayashi, O. Wada, Y. Tateishi, L. Kitada, Y. Yamamoto, H. Takashima, A. Murayama, T. Yano, T. Baba, et al. Full Activation of Estrogen Receptor {alpha} Activation Function-1 Induces Proliferation of Breast Cancer Cells J. Biol. Chem., July 11, 2003; 278(29): 26704 - 26714. [Abstract] [Full Text] [PDF]

				P. Webb, P. Nguyen, and P. J. Kushner Differential SERM Effects on Corepressor Binding Dictate ERalpha Activity in Vivo J. Biol. Chem., February 21, 2003; 278(9): 6912 - 6920. [Abstract] [Full Text] [PDF]

				M. A. Loven, N. Muster, J. R. Yates, and A. M. Nardulli A Novel Estrogen Receptor {alpha}-Associated Protein, Template-Activating Factor I{beta}, Inhibits Acetylation and Transactivation Mol. Endocrinol., January 1, 2003; 17(1): 67 - 78. [Abstract] [Full Text] [PDF]

				N. Vasudevan, S. Ogawa, and D. Pfaff Estrogen and Thyroid Hormone Receptor Interactions: Physiological Flexibility by Molecular Specificity Physiol Rev, October 1, 2002; 82(4): 923 - 944. [Abstract] [Full Text] [PDF]

				L. D. Haro and R. Janknecht Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter Nucleic Acids Res., July 1, 2002; 30(13): 2972 - 2979. [Abstract] [Full Text] [PDF]

				Y. Yamamoto, O. Wada, M. Suzawa, Y. Yogiashi, T. Yano, S. Kato, and J. Yanagisawa The Tamoxifen-responsive Estrogen Receptor alpha Mutant D351Y Shows Reduced Tamoxifen-dependent Interaction with Corepressor Complexes J. Biol. Chem., November 9, 2001; 276(46): 42684 - 42691. [Abstract] [Full Text] [PDF]

				J. M. Fitts, R. M. Klein, and C. A. Powers Estrogen and Tamoxifen Interplay with T3 in Male Rats: Pharmacologically Distinct Classes of Estrogen Responses Affecting Growth, Bone, and Lipid Metabolism, and Their Relation to Serum GH and IGF-I Endocrinology, October 1, 2001; 142(10): 4223 - 4235. [Abstract] [Full Text] [PDF]

				J. Zilliacus, E. Holter, H. Wakui, H. Tazawa, E. Treuter, and J.-A. Gustafsson Regulation of Glucocorticoid Receptor Activity by 14-3-3-Dependent Intracellular Relocalization of the Corepressor RIP140 Mol. Endocrinol., April 1, 2001; 15(4): 501 - 511. [Abstract] [Full Text]

				L. I. McKay and J. A. Cidlowski CBP (CREB Binding Protein) Integrates NF-{kappa}B (Nuclear Factor-{kappa}B) and Glucocorticoid Receptor Physical Interactions and Antagonism Mol. Endocrinol., August 1, 2000; 14(8): 1222 - 1234. [Abstract] [Full Text]

				P. Webb, P. Nguyen, C. Valentine, R. V. Weatherman, T. S. Scanlan, and P. J. Kushner An Antiestrogen-responsive Estrogen Receptor-alpha Mutant (D351Y) Shows Weak AF-2 Activity in the Presence of Tamoxifen J. Biol. Chem., November 22, 2000; 275(48): 37552 - 37558. [Abstract] [Full Text] [PDF]